Experimental drug boosts Cancer-Killing cells in lymphoma trial
NCT ID NCT05359211
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how well the combination works. NKTR-255 is designed to strengthen the immune system's cancer-fighting cells, while the CAR-T cells are engineered to recognize and destroy lymphoma cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NKTR-255 (an immune-boosting drug) and lisocabtagene maraleucel (CAR-T cells that target cancer)
- What this could lead to
- If it works, this combination could improve the ability of CAR-T therapy to fight hard-to-treat lymphoma, potentially leading to better remission rates.
- What could go wrong
- This is a very early (Phase 1) trial with only 27 people, so results may not apply broadly. There is also a risk of serious side effects from the immune system overreacting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a single shot build a cancer army inside the body?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients